On Monday, Shares of Amkor Technology, Inc. (NASDAQ:AMKR), gained 1.33% to $6.85.
Amkor Technology, declared that it will take part in the following investor conferences:
- Morgan Stanley Leveraged Finance Conference on Thursday, June 4, 2015. Amkor’s presentation will occur at 3:30 pm Central Time (4:30 pm Eastern Time) at The Roosevelt New Orleans, New Orleans, LA.
- Barclays High Yield Bond & Syndicated Loan Conference on Friday, June 12, 2015. Amkor’s presentation will occur at 8:50 am Mountain Time (10:50 am Eastern Time) at The Broad-moor in Colorado Springs, CO.
Amkor Technology, Inc. provides outsourced semiconductor packaging and test services in the United States, China, Ireland, Japan, Singapore, Taiwan, Thailand, and internationally.
Shares of Comerica Incorporated (NYSE:CMA), declined -1.12% to $ 48.40, during its last trading session.
Comerica Bank’s Texas Economic Activity Index eased again in March, decreasing 3.4 percentage points to a level of 101.1. March’s reading is 29 points, or 39 percent, above the index cyclical low of 72.6. The index averaged 105.1 points for all of 2014, four and four-fifths points above the average for full-year 2013. February’s index reading was 104.6.
The Texas Economic Activity Index comprises of eight variables, as follows: nonfarm payrolls, exports, hotel occupancy rates, ongoing claims for unemployment insurance, housing starts, sales tax revenues, home prices, and the Baker Hughes rotary rig count. All data are seasonally adjusted, as necessary, and indexed to a base year of 2008. Nominal values have been converted to constant dollar values. Index levels are expressed in terms of three-month moving averages.
Comerica Incorporated, through its auxiliaries, provides various financial products and services. It operates through three segments: Business Bank, Retail Bank, and Wealth Administration.
At the end of Monday’s trade, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), gained 0.25% to $ 239.36.
Valeant Pharmaceuticals, declared the presentation of new results, supporting its EMA and FDA approved Hereditary Angioedema therapy RUCONEST, at the 9th C1- Inhibitor Deficiency Workshop that took place in Budapest, Hungary, 28-31 May 2015.
Several abstracts, counting two oral presentations, were presented, which demonstrate Pharming’s ongoing commitment to advance innovative science in HAE, with the aim of addressing noteworthy clinical needs and improving patient care.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a sub-gingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Finally, Monster Beverage Corp (NASDAQ:MNST), ended its last trade with -0.09% loss, and close at $ 127.17.
Monster Beverage Corporation, stated financial results for the first quarter ended March 31, 2015.
In August 2014, Monster Beverage and The Coca-Cola Company reached definitive agreements for a long-term planned partnership to accelerate growth for both companies in the global energy drink category. The transaction, which is subject to customary closing conditions, is predictable to close in the second quarter of 2015. In early February 2015, in accordance with its existing agreements with certain affected third-party distributors, the Company sent notices of termination to the applicable third-party distributors in the U.S., providing for the termination of their respective distribution agreements, to be effective at various dates starting in March 2015.
Monster Beverage Corporation, through its auxiliaries, develops, markets, sells, and distributes alternative beverage category beverages in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
